Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FERROCLEAR
NCT07332091Phase 2Active, not recruiting
- Sponsor
- CSL Limited
- Start
- Jan 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial of vamifeport in hereditary hemochromatosis (HH) (3 arms), sponsored by CSL Limited. Primary endpoint: Change from baseline in magnetic resonance imaging (MRI)-based liver iron concentration (LIC) at Day 360. Started Jan 2026; status: active, not recruiting.
02
Drugs
vamifeport
03
Conditions
hereditary hemochromatosis (HH)
Beyond the preview
Go deeper on NCT07332091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07332091.